Rocket Lab (RKLB) director Merline Saintil reports planned stock sales

Rhea-AI Filing Summary

Rocket Lab Corp director Merline Saintil reported multiple stock sales carried out under a pre-arranged Rule 10b5-1 trading plan. On December 17, 2025, she sold blocks of 2,533, 1,767, 500 and 200 shares of Rocket Lab common stock in open-market transactions.

The reported weighted-average sale prices were $53.8164, $54.824, $55.668 and $56.48, with each group of trades executed across price ranges detailed in the footnotes. After these transactions, Saintil directly beneficially owned 393,529 shares of Rocket Lab common stock.

The filing notes that these sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2025, which is designed to allow insiders to sell shares according to a preset schedule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saintil Merline

(Last) (First) (Middle)

3881 MCGOWEN STREET

(Street)

LONG BEACH CA 90808

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rocket Lab Corp [ RKLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2025		S		2,533(1)	D	$53.8164(2)	395,996	D
Common Stock	12/17/2025		S		1,767(1)	D	$54.824(3)	394,229	D
Common Stock	12/17/2025		S		500(1)	D	$55.668(4)	393,729	D
Common Stock	12/17/2025		S		200(1)	D	$56.48(5)	393,529	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the sale of shares which occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.3600 to $54.2900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.3700 to $55.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $55.3700 to $55.8600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $56.3700 to $56.5900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	By: /s/ Arjun Kampani as Attorney-in-Fact For: Merline Saintil	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rocket Lab Corp (RKLB) disclose in this Form 4?

The filing shows that director Merline Saintil sold several blocks of Rocket Lab common stock on December 17, 2025, in open-market transactions.

How many Rocket Lab (RKLB) shares did Merline Saintil sell on December 17, 2025?

She reported sales of 2,533, 1,767, 500 and 200 shares of Rocket Lab common stock in separate transactions on that date.

At what prices were the Rocket Lab (RKLB) shares sold by Merline Saintil?

The reported weighted-average sale prices were $53.8164, $54.824, $55.668 and $56.48, each based on multiple trades within stated price ranges.

How many Rocket Lab (RKLB) shares does Merline Saintil own after these sales?

Following the reported transactions, Merline Saintil directly beneficially owned 393,529 shares of Rocket Lab common stock.

Were the Rocket Lab (RKLB) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states that the sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2025.

Does the Form 4 report any Rocket Lab (RKLB) derivative securities transactions?

No derivative securities transactions are listed; the table for derivative securities does not show any acquired or disposed positions.